Quest Diagnostics (NYSE:DGX) Stock: Insider Michael Deppe Sells 11,776 Shares

Quest Diagnostics Incorporated (NYSE:DGX - Get Free Report) CAO Michael Deppe sold 11,776 shares of the business's stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $260.17, for a total transaction of $3,063,761.92. Following the transaction, the chief accounting officer directly owned 35,203 shares of the company's stock, valued at $9,158,764.51. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Quest Diagnostics Price Performance

NYSE DGX opened at $261.67 on Tuesday. The company has a 50-day moving average price of $241.72 and a two-hundred day moving average price of $215.98. Quest Diagnostics Incorporated has a 52 week low of $171.18 and a 52 week high of $263.19. The stock has a market cap of $28.79 billion, a price-to-earnings ratio of 23.52, a price-to-earnings-growth ratio of 2.32 and a beta of 0.55. The company has a current ratio of 1.70, a quick ratio of 1.58 and a debt-to-equity ratio of 0.70.




Quest Diagnostics (NYSE:DGX - Get Free Report) last released its quarterly earnings results on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, beating analysts' consensus estimates of $2.87 by $0.13. The company had revenue of $3.10 billion for the quarter, compared to analysts' expectations of $3.05 billion. Quest Diagnostics had a return on equity of 16.21% and a net margin of 9.53%. The business's revenue for the quarter was up 10.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.60 earnings per share. Analysts forecast that Quest Diagnostics Incorporated will post 11.29 EPS for the current year.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, January 27th. Investors of record on Tuesday, January 12th will be given a $0.86 dividend. This represents a $3.44 annualized dividend and a yield of 1.3%. The ex-dividend date is Tuesday, January 12th. Quest Diagnostics's dividend payout ratio (DPR) is currently 34.26%.

Institutional Trading of Quest Diagnostics

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new position in Quest Diagnostics during the 2nd quarter valued at $1,965,923,000. Bank of America Corp DE acquired a new position in shares of Quest Diagnostics during the 2nd quarter valued at $410,151,000. Legal & General Group Plc acquired a new position in shares of Quest Diagnostics during the 2nd quarter valued at $151,986,000. Bank of New York Mellon Corp acquired a new position in shares of Quest Diagnostics during the 2nd quarter valued at $133,388,000. Finally, Deutsche Bank AG bought a new stake in shares of Quest Diagnostics in the 2nd quarter worth $124,180,000. 88.06% of the stock is owned by institutional investors and hedge funds.

Recent Quest Diagnostics Headlines

Here are a few of the latest headlines about DGX:

  • Positive Sentiment: Recent quarterly results provided support: Quest reported EPS of $3.00 and revenue of $3.10 billion, both above estimates, with revenue up 10% year over year.
  • Neutral Sentiment: Chief Accounting Officer Michael Deppe sold 11,776 shares for about $3.06 million, reducing his holding by 25.07%. The trade was made under a pre-arranged Rule 10b5-1 plan, which makes it less indicative of a sudden change in outlook. SEC filing
  • Negative Sentiment: Zacks Research lowered several future EPS forecasts, including Q1 2027 to $2.61 from $2.72, FY2027 to $11.69 from $11.73, and FY2028 to $12.77 from $12.90. The reductions are small but suggest slightly softer expectations for earnings growth. Q1 EPS estimates cut

Analysts Set New Price Targets

Several brokerages have weighed in on DGX. Mizuho lifted their target price on Quest Diagnostics from $235.00 to $260.00 and gave the company an "outperform" rating in a research note on Friday, July 24th. JPMorgan Chase & Co. increased their price target on Quest Diagnostics from $220.00 to $250.00 and gave the stock a "neutral" rating in a research note on Tuesday, July 28th. Argus set a $260.00 price target on Quest Diagnostics in a research note on Wednesday, July 29th. Wall Street Zen raised Quest Diagnostics from a "hold" rating to a "buy" rating in a report on Tuesday, July 28th. Finally, Barclays lifted their price objective on shares of Quest Diagnostics from $250.00 to $260.00 and gave the company an "overweight" rating in a research note on Wednesday, October 7th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $248.70.

Read Our Latest Stock Report on DGX

About Quest Diagnostics

(Get Free Report)

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing. The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.

Featured Articles

Insider Buying and Selling by Quarter for Quest Diagnostics (NYSE:DGX)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Quest Diagnostics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Quest Diagnostics and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles